Valuation: Immunovia AB

Market Cap 118M 12.14M 10.66M 9.91M 9.1M 17.09M 1.17B 17.36M 45.99M 575M 45.56M 44.58M 1.99B P/E 2026 *
-1.75x
P/E 2027 * -4.38x
Enterprise Value 50.72M 5.23M 4.59M 4.27M 3.92M 7.36M 504M 7.48M 19.81M 248M 19.63M 19.21M 856M EV / Sales 2026 *
15.8x
EV / Sales 2027 * 2.53x
Free-Float
89.3%
Yield 2026 *
-
Yield 2027 * -
1 day-32.03%
1 week+16,951.28%
Current month+16,370.59%
1 month+16,806.78%
3 months+15,860.00%
6 months+14,725.82%
Current year+13,658.62%
1 week 0.18
Extreme 0.176
0.32
1 month 0.18
Extreme 0.176
0.32
Current year 0.15
Extreme 0.1544
0.32
1 year 0.15
Extreme 0.1544
0.92
3 years 0.15
Extreme 0.1544
2.78
5 years 0.15
Extreme 0.1544
139.14
10 years 0.15
Extreme 0.1544
292
Manager TitleAgeSince
Chief Executive Officer 53 28/04/2023
Chief Tech/Sci/R&D Officer 55 28/04/2024
Chief Tech/Sci/R&D Officer 54 30/01/2024
Director TitleAgeSince
Director/Board Member 72 08/12/2016
Chairman 69 25/05/2023
Director/Board Member 51 31/12/2020
Change 5-day change 1-year change 3-year change Capi.($)
-32.03%+16,951.28% - - 12.14M
-0.36%-9.20%+15.65%-38.35% 15.54B
-7.90%+5.00%-2.15%+84.41% 1.65B
-3.20%-7.65%-41.40%-81.89% 1.09B
-1.41%-4.66%-38.57%+10.83% 948M
-3.39%-5.61%-45.48%-55.93% 609M
-2.46%-5.34%-51.05%-58.53% 505M
+1.87%+3.51%+39.11%-52.08% 460M
+1.52%-3.98%-57.46%-61.30% 365M
+0.72%-4.89%-22.14%-37.78% 344M
Average -4.66%-3.58%-22.61%-32.29% 2.39B
Weighted average by Cap. -1.18%-7.28%+4.35%-30.65%

Financials

2026 *2027 *
Net sales 3.2M 330K 290K 269K 247K 465K 31.77M 472K 1.25M 15.62M 1.24M 1.21M 54.01M 17.3M 1.78M 1.57M 1.46M 1.34M 2.51M 172M 2.55M 6.76M 84.45M 6.7M 6.55M 292M
Net income -91M -9.38M -8.24M -7.66M -7.03M -13.21M -904M -13.42M -35.55M -444M -35.22M -34.46M -1.54B -82M -8.45M -7.43M -6.91M -6.34M -11.91M -814M -12.09M -32.04M -400M -31.74M -31.05M -1.38B
Net Debt -67M -6.91M -6.07M -5.64M -5.18M -9.73M -665M -9.88M -26.18M -327M -25.93M -25.37M -1.13B -74M -7.63M -6.7M -6.23M -5.72M -10.74M -735M -10.91M -28.91M -361M -28.64M -28.02M -1.25B
Logo Immunovia AB
Immunovia AB (publ) is a Sweden-based diagnostic company that is developing and commercializing blood tests for the early detection of cancer and autoimmune diseases based on Immunovia’s test platform called IMMray. Tests are based on antibody biomarker microarray analysis using machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a disease biomarker signature. Immunovia Dx Laboratories locations in USA and Sweden provides laboratory testing services in two accredited reference laboratories.
Employees
17
Date Price Change Volume
24/07/26 SEK 0.1760 -5.98% 3,000

Quarterly revenue - Rate of surprise